Publications by authors named "J A Journee-de Korver"
Article Synopsis
- The study investigates the impact of psoriasis on patients' work and daily life activities as they start using biological treatments.
- Data from 194 patients showed that after beginning treatment, disease activity significantly decreased, yet work participation remained lower than the general population.
- Although employed patients exhibited improved productivity, nearly half still faced challenges in daily activities, with no significant changes observed over time.
The perceived impact of being a chaplain-researcher on professional practice.
J Health Care Chaplain
January 2024
As research has become part of chaplaincy, many chaplains become involved in research, often in the double-role of chaplain-researcher. Despite the increase of involvement in research, how conducting research benefits chaplains' professional care for clients has not been studied. The present study aimed to describe how chaplains perceive the impact of participation in the Dutch Case Studies Project (CSP) on their professional expertise and positioning in the institution.
View Article and Find Full Text PDFBackground: Psoriasis is a common inflammatory disease in any age group, but also in older patients (≥ 65 years of age). Since older patients are often excluded from clinical trials, limited data specifically on this growing population are available, e.g.
View Article and Find Full Text PDFArticle Synopsis
- A study was conducted to compare the effectiveness of different biologic therapies for psoriasis, including IL17-inhibitors and TNF-α-inhibitors, using real-world data.
- Researchers analyzed data from 1,080 treatment episodes involving 700 psoriasis patients to assess outcomes like the mean Psoriasis Area and Severity Index (PASI) and how many patients achieved PASI90 or PASI75.
- Results showed that patients on adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab had better outcomes than those on etanercept, with ixekizumab and guselkumab leading to even higher rates of achieving PASI90 compared to the other biologics